FDA suggests protocol for off-label data

Article

The Food and Drug Administration this month proposed a new protocol that would enable medical drug and device companies to release off-label information about their commercial drugs, biologics, and medical devices. The agency's proposal could make it

The Food and Drug Administration this month proposed a new protocol that would enable medical drug and device companies to release off-label information about their commercial drugs, biologics, and medical devices. The agency's proposal could make it easier for companies to inform physicians about new potential uses for products before those applications receive regulatory approval.

The FDA's proposal arises out of the 1997 Food and Drug Administration Modernization Act (FDAMA), and stipulates the particular type of unapproved-use data that can be released. If the new rules are adopted, companies will be able to disseminate information about their products' off-label uses, provided the information pertains to products already approved, licensed, or cleared by the FDA.

Data will be presented in unedited peer-reviewed medical journal articles describing clinical investigations that medical experts consider reliable, and must not mislead the public or pose a threat to public health. The information must also be obtained with permission from other manufacturers who have conducted clinical research. Companies will be required to state clearly that the product's new use is not FDA-approved.

Under the new protocol, a copy of the information will be submitted to the FDA 60 days before the company releases it to the public. The FDA could order the company to stop distributing the information if the agency determined that the off-label use was not effective or posed a health risk. The FDA's proposed rules are open to public comment through late July.

Newsletter

Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.

Recent Videos
SNMMI: Emerging PET Insights on Neuroinflammation with Progressive Apraxia of Speech (PAOS) and Parkinson-Plus Syndrome
Improving Access to Nuclear Imaging: An Interview with SNMMI President Jean-Luc C. Urbain, MD, PhD
SNMMI: 18F-Piflufolastat PSMA PET/CT Offers High PPV for Local PCa Recurrence Regardless of PSA Level
SNMMI: NIH Researcher Discusses Potential of 18F-Fluciclovine for Multiple Myeloma Detection
SNMMI: What Tau PET Findings May Reveal About Modifiable Factors for Alzheimer’s Disease
Emerging Insights on the Use of FES PET for Women with Lobular Breast Cancer
Can Generative AI Reinvent Radiology Reporting?: An Interview with Samir Abboud, MD
Mammography Study Reveals Over Sixfold Higher Risk of Advanced Cancer Presentation with Symptom-Detected Cancers
Combining Advances in Computed Tomography Angiography with AI to Enhance Preventive Care
Study: MRI-Based AI Enhances Detection of Seminal Vesicle Invasion in Prostate Cancer
Related Content
© 2025 MJH Life Sciences

All rights reserved.